TERT and melanoma: Of the utmost interest, we observed that specific TERT promoter mutation c.-124C>T displayed a statistically significant correlation with MAPK inhibitor treatment efficacy, specifically in a subset of BRAFV600 melanoma patients that had poorer PFS and OS.